OOIR: Observatory of International Research

Papers

(The median citation count of Translational Neurodegeneration is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	244
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	166
Exploring the skin as an open window onto neurodegenerative diseases	159
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease	148
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	147
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	146
Attenuating α-synuclein pathology in mice with in situ engineered astrocytes	124
Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus–response in spinal muscular atrophy	117
Age-dependent removal of Atg9-containing vesicle accumulations in motoneuron disease models by physical exercise	117
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	111
Axonopathy: mechanisms and potential therapeutic targets for neurodegenerative diseases	108
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	106
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	105
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	88
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	88
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	82
Role of dopamine in the pathophysiology of Parkinson’s disease	81
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients	77
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	74
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	73
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	72
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	72
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies	71
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	68
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	68

Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease	66
Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China	66
Cortical layer multi-parameter analysis of neurovascular impairments in AD/ADRD rodent model with in vivo optical imaging	65
Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	61
Inflammasomes in neurodegenerative diseases	56
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside	56
Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications	55
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	55
Nose-to-brain drug delivery: from bench to bedside	53
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures	52
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	49
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study	49
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease	48
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease	47
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes	47
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	44
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	44
Molecular mechanisms of exercise-induced improvements in Alzheimer’s disease: a focus on lipid homeostasis	44
Peripheral proteinopathy in neurodegenerative diseases	44
The emerging role and therapeutic targeting of autophagy-lysosome pathway in the pathogenesis of Parkinson’s disease	43
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	43
Multidimensional biomarkers for multiple system atrophy: an update and future directions	42
Mesenchymal stromal cells and neuroinflammation: a multimodal approach to neuroprotection and future therapeutic horizons	42
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory	41
Tau conformation, distribution and PET imaging correlations in progressive supranuclear palsy	41
Perivascular spaces relate to the course and cognition of Huntington’s disease	39
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	38
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	37
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	37
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system	37
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases	36
Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer’s disease	36
Aging-dependent YAP1 reduction contributes to AD pathology by upregulating the Nr4a1-AKT/GSK-3β axis	35
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology	34
Deficient AMPK-SENP1-Sirt3 signaling impairs mitochondrial complex I function in Parkinson’s disease model	33
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	32
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	32
Role of extracellular vesicle-carried ncRNAs in the interactive ‘dialogue’ within the brain and beyond: emerging theranostic epigenetic modifiers in brain-derived nanoplatforms	31
Extracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity	31
In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use	31
Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease	31
Plasma proteomic signatures as predictors of dementia risk in individuals with sleep apnea: a cohort study	30
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics	29
Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease	29
Nootropic foods in neurodegenerative diseases: mechanisms, challenges, and future	27
Mapping cellular vulnerability in Parkinson’s disease using retro-AAVs and preformed α-synuclein fibrils	27
Emerging role of senescent microglia in brain aging-related neurodegenerative diseases	27
Alterations in sleep-activity cycles and clock gene expression across the synucleinopathy spectrum	26
Biases in α-synuclein immuno-quantitation: a core problem for basic and ancillary studies of Parkinson’s disease and multiple system atrophy	26
Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics	25

Stress granules: emerging players in neurodegenerative diseases	25
Linking APOE4/4 genotype to microglial lipid droplets and neurotoxicity in Alzheimer’s disease	25
N-terminally acetylated Met11-Tau: a new pathological truncated Tau species with functional relevance in Alzheimer's disease	25
Retrotransposon: an insight into neurological disorders from perspectives of neurodevelopment and aging	24
Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine	24
Increased cysteinyl-tRNA synthetase drives neuroinflammation in Alzheimer’s disease	24
Microglia in the crosstalk between peripheral and central nervous systems in Parkinson’s disease	24
Correction: CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation	24
CSF biomarkers of reactive glial cells are associated with blood–brain barrier leakage and white matter lesions	24
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease	23
Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges	23
Myelin repair in Alzheimer’s disease: a review of biological pathways and potential therapeutics	23
Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson’s disease in Drosophila	23
TRPV1 alleviates APOE4-dependent microglial antigen presentation and T cell infiltration in Alzheimer's disease	22
Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia	22
Endosomal traffic disorders: a driving force behind neurodegenerative diseases	22
Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases	22
Positive modulation of sigma-1 receptor: a new weapon to mitigate disease progression in amyotrophic lateral sclerosis	21
Disease–disease interactions: molecular links of neurodegenerative diseases with cancer, viral infections, and type 2 diabetes	21
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease	21
GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model	21
CRISPR base editing-mediated correction of a tau mutation rescues cognitive decline in a mouse model of tauopathy	20
Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease	20
APOE ε4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer’s disease	20
Glutathione oxidation in cerebrospinal fluid as a biomarker of oxidative stress in amyotrophic lateral sclerosis	20
Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise	20
Research progress on the role of extracellular vesicles in neurodegenerative diseases	19
N-terminus α-synuclein detection reveals new and more diverse aggregate morphologies in multiple system atrophy and Parkinson’s disease	19
Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification	19
Targeting the glymphatic system: Aβ accumulation and phototherapy strategies across different stages of Alzheimer’s disease	19
Alleviating the unwanted effects of oxidative stress on Aβ clearance: a review of related concepts and strategies for the development of computational modelling	18
Putative novel CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort	18
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases	17
N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology	16
Transcranial alternating current stimulation (tACS) at gamma frequency: an up-and-coming tool to modify the progression of Alzheimer’s Disease	16
Long-term exercise enhances meningeal lymphatic vessel plasticity and drainage in a mouse model of Alzheimer's disease	16
Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	15
Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases	15
The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases	15
Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease	15
Optogenetic induction of TDP-43 aggregation impairs neuronal integrity and behavior in Caenorhabditis elegans	15
Beyond amyloid: nanobody-mediated neuroinflammatory therapy for Alzheimer’s disease	15
Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson’s disease and multiple system atrophy	15
Cyclooxygenase-1 deletion in 5 × FAD mice protects against microglia-induced neuroinflammation and mitigates cognitive impairment	14
Can exercise benefits be harnessed with drugs? A new way to combat neurodegenerative diseases by boosting neurogenesis	14
Chronic subthalamic nucleus deep brain stimulation reduces pathological TrkB aggregates in a Parkinson’s disease rat model	14
Drug repurposing for disease-modifying effects in multiple system atrophy	14
Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis	14
SSEA3 and CD105 positivity are associated with the treatment potency of human neural crest-derived nasal turbinate stem cells for Alzheimer’s disease	14
Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms	13
Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis	13
Circadian disruption and sleep disorders in neurodegeneration	13
Updates in Alzheimer's disease: from basic research to diagnosis and therapies	13